K.H. Lee

Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer

Shunichi Sugawara, J.-S. Lee, Jin‐Hyoung Kang et al. · Annals of Oncology · 2021 · 192 citations · Full text

Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC

Naiyer A. Rizvi, B. Chul Cho, Niels Reinmuth et al. · Annals of Oncology · 2018 · 92 citations · Full text

Cancer Immunosurveillance, Pd-l1 Expression, Medicine +14

LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2

Jeffrey D. Bradley, Shunichi Sugawara, K.H. Lee et al. · ESMO Open · 2024 · 61 citations · Full text

Final Results, Radiation Medicine, Consolidation D +14

OA04.07 Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial

Naiyer A. Rizvi, Byoung Chul Cho, Niels Reinmuth et al. · Journal of Thoracic Oncology · 2019 · 56 citations · Full text

Clinical Immunology, Immunogenetics, Autoimmune Disease +11

Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA

Sundar Ramalingam, Thanyanan Reungwetwattana, B. Chewaskulyong et al. · Annals of Oncology · 2017 · 33 citations · Full text

Osimertinib Vs Standard, First-line Therapy, Oncology +8